2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

2:30PM-4:00PM: Abstract Number: 2011

Enteric-Coated Mycophenolate Sodium Versus Azathioprine for Patients with Moderate/Severe Active Systemic Lupus Erythematosus: Results from a Phase 3, Randomized, Parallel, Multicentre Study

Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 2016

Esophageal Disease in Systemic Sclerosis: Does Heritability Play a Role?

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics II

2:30PM-4:00PM: Abstract Number: 2005

Exploring the Window of Opportunity for Drug-Free Clinical Remission in Patients with Active, Very Early Peripheral Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III: Axial Spondyloarthritis – Clinical

2:30PM-4:00PM: Abstract Number: 2019

Faces in Motion: Clinical Subtyping in Scleroderma Using Changes in Forced Vital Capacity

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics II

2:30PM-4:00PM: Abstract Number: 1961

Identification of Novel Genetic Susceptibility Loci in Primary Antiphospholipid Syndrome

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 1985

IL-18 Elevation in Macrophage Activation Syndrome: Human Evidence for a Chronic Set-Point and Murine Evidence for a Non-Hematopoietic Source

Pediatric Rheumatology – Pathogenesis and Genetics

2:30PM-4:00PM: Abstract Number: 1977

Impact of Ultrasound in Treatment Decision of Rheumatoid Arthritis Assessed in Routine Clinical Practice

Imaging of Rheumatic Diseases II: Ultrasound in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 2000

Incidence of Cancer in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Safety and Cost Effectiveness

2:30PM-4:00PM: Abstract Number: 1990

Increased Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis over a 15 Year Time Period That Is Comparable to Type 2 Diabetes

Rheumatoid Arthritis – Clinical Aspects II: Risk and Impact of Comorbidity

2:30PM-4:00PM: Abstract Number: 1973

Intramuscular Versus Ultrasound Guided Peritendinous Glucocorticoid Injection for Tenosynovitis in Patients with Rheumatoid Arthritis – a Randomised, Double-Blind, Controlled Study

Imaging of Rheumatic Diseases II: Ultrasound in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 2004

Is Disease Activity Associated with Work Productivity Loss, Presenteeism and Absenteeism in Patients with Early Axial Spondyloarthritis? Results from the Spondyloarthritis Caught Early (SPACE)-Cohort

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III: Axial Spondyloarthritis – Clinical

2:30PM-4:00PM: Abstract Number: 1974

Is Ultrasound of the Hands Enough to Reveal Ongoing Subclinical Inflammation in Rheumatoid Arthritis Patients in Clinical Remission According to Composite Scores?

Imaging of Rheumatic Diseases II: Ultrasound in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 1998

Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis Indicate a Similar Safety but a Different Drug Retention Between Abatacept, Rituximab and Tocilizumab

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Safety and Cost Effectiveness

2:30PM-4:00PM: Abstract Number: 2025

Lupus Education Advancement Project (LEAP): Rheumatology Fellows Serving As Educators Increased Knowledge and Efficiency in Lupus Recognition and Referral By Providers in Primary and Emergency Care

ARHP III: Education and Community Programs

2:30PM-4:00PM: Abstract Number: 2020

Making the Case for Self-Management Education: Marketing Lessons Learned from Qualitative Research

ARHP III: Education and Community Programs

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].